GAMAMABS PHARMA

GamaMabs is a privately held immuno-oncology biotechnology company specialized in the development of optimized monoclonal antibodies (mAb). Its lead program is GM102 (formerly 3C23K), a mAb targeting the receptor of the anti-Müllerian hormone (AMHR2) in gynecological cancers, currently in phase Ia/Ib stage. GM102 has increased tumor cell killing properties through the activation of immune system cells, thanks to its EMABling® glyco-engineering technology. Founded in June 2013 in Toulouse (Fr... ance), GamaMabs employs 7 professionals with a sound and successful experience in preclinical and clinical development up to registration. GamaMabs has established collaborations with leading academic and private partners in order to develop its programs, such as Institut Gustave Roussy, Institut Curie, Institut Cochin, Institut de Recherche en Cancérologie de Montpellier (IRCM) or Mass General Hospital (Boston). GamaMabs values high-potential technologies initially developed by LFB BIOTECHNOLOGIES, a French Biopharma specialized in Hemostasis and Immunological Disorders. LFB developed two original patented platforms for the generation of mAbs with high efficiency (EMABling®) and/or long duration of action (HuMabFc), as well as a pipeline of several products stemming from those technologies. For strategic reason LFB decided to transfer some assets and rights to use its mAbs platforms and mAbs Oncology projects to GamaMabs. The main objective of GamaMabs is to develop its mAbs up to the stage of Clinical Proof of Concept.
GAMAMABS PHARMA
Industry:
Biotechnology Health Care Therapeutics
Founded:
2013-01-01
Address:
Toulouse, Midi-Pyrenees, France
Country:
France
Website Url:
http://www.gamamabs.com
Total Employee:
1+
Status:
Active
Contact:
+33 (0)5 31 61 60 69
Email Addresses:
[email protected]
Total Funding:
18.1 M EUR
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible LetsEncrypt WordPress Apache Wordpress Plugins Google Maps PHP Google Maps API OVH
Similar Organizations
Cedilla Therapeutics
Cedilla Therapeutics is a biotechnology company that develops targeted small molecules for the treatment of cancer and other diseases.
Current Advisors List
Current Employees Featured
Founder
Investors List
Andera Partners
Andera Partners investment in Series B - GamaMabs Pharma
Bpifrance
Bpifrance investment in Series A - GamaMabs Pharma
Official Site Inspections
http://www.gamamabs.com
- Host name: 104.21.64.1
- IP address: 104.21.64.1
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago

More informations about "GamaMabs Pharma"
GamaMabs Pharma - Crunchbase Company Profile & Funding
GamaMabs is a privately held immuno-oncology biotechnology company specialized in the development of optimized monoclonal antibodies (mAb). Its lead program is GM102 (formerly …See details»
GamaMabs Pharma - LinkedIn
Employees at GamaMabs Pharma Jean-Michel Petit Directeur Associé IRDI Capital Investissement, financement en amorçage des entreprises deeptech du Sud-OuestSee details»
GamaMabs Pharma - VentureRadar
GamaMabs Pharma is a clinical-stage immuno-oncology company developing optimized therapeutic antibodies for the treatment of cancer. GamaMabs’ lead project is the monoclonal …See details»
GAMAMABS PHARMA Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for GAMAMABS PHARMA of TOULOUSE, OCCITANIE. Get the latest business insights from Dun & Bradstreet.See details»
GamaMabs Pharma - The Org
GamaMabs Pharma is a clinical-stage immuno-oncology company that developes optimized therapeutic antibodies for the treatment of cancer. Industries. Biotechnology, Health Care +1. …See details»
GamaMabs Pharma - Funding, Financials, Valuation & Investors
GamaMabs Pharma is a clinical-stage immuno-oncology company that developes optimized therapeutic antibodies for the treatment of cancer. Search Crunchbase. Start Free Trial . …See details»
GamaMabs Pharma Company Profile - Office Locations, …
GamaMabs Pharma is a clinical-stage immuno-oncology company. It develops therapeutic antibodies for the treatment of cancer. The company develops low-fucose EMABling …See details»
GAMAMABS PHARMA Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for GAMAMABS PHARMA of NEUILLY SUR SEINE, ILE DE FRANCE. Get the latest business insights from …See details»
GamaMabs Pharma Overview | SignalHire Company Profile
GamaMabs Pharma is a private company that has been in the industry for 11 years. The company currently specializes in the Biotechnology area. ... Organization Website: gamamabs.com : …See details»
GamaMabs Pharma - Products, Competitors, Financials, Employees ...
GamaMabs Pharma's latest funding round is Incubator/Accelerator. How much did GamaMabs Pharma raise? GamaMabs Pharma raised a total of $21.61M. Who are the investors of …See details»
GamaMabs Pharma - VentureRadar
GamaMabs Pharma is a clinical-stage immuno-oncology company developing optimized therapeutic antibodies for the treatment of cancer. GamaMabs’ lead project is the monoclonal …See details»
GamaMabs Pharma SA - Drug pipelines, Patents, Clinical trials
ALAMEDA, Calif. & TOULOUSE, France--(BUSINESS WIRE)-- Exelixis, Inc. (Nasdaq: EXEL) and GamaMabs Pharma SA today announced that they have entered into an agreement under …See details»
GamaMabs Pharma - Crunchbase
GamaMabs Pharma is a clinical-stage immuno-oncology company that developes optimized therapeutic antibodies for the treatment of cancer. Search Crunchbase. Start Free Trial . …See details»
GAMAMABS PHARMA - IXO PE
GamaMabs Pharma, société constituée en 2013, exploite une licence sur des programmes développés par le LFB Biotechnologies. Ayant pour objectif de développer des anticorps …See details»
GamaMabs - Biotech.info
GamaMabs’ lead project is the monoclonal antibody (mAb) GM102 which targets Anti-Müllerian Human Receptor II (AMHRII), an unaddressed specific target in cancer. The company …See details»
GAMAMABS PHARMA - IXO PE
GamaMabs Pharma, a company incorporated in 2013, has licensed programs developed by LFB Biotechnologies. With the objective of developing monoclonal antibodies for the treatment of …See details»
GamaMabs Pharma Launches with Funding - VC News Daily
GamaMabs Pharma benefits from an exclusive global sublicense from the LFB group for the monoclonal antibody 3C23K and is supported by LFB group's EMABling platform. In exchange …See details»
GamaMabs Pharma - Contacts, Employees, Board Members
Organization. GamaMabs Pharma . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 2. Number of …See details»
GamaMabs Pharma - Tech Stack, Apps, Patents & Trademarks
GamaMabs Pharma is a clinical-stage immuno-oncology company that developes optimized therapeutic antibodies for the treatment of cancer. Search Crunchbase. Start Free Trial . …See details»
GamaMabs Pharma announces presentation of murlentamab …
Jul 5, 2019 GamaMabs Pharma, a French immuno-oncology biotechnology company, is the leader in the development of optimized antibodies targeting AMHRII for the treatment of …See details»